Med BioGene Receives Funding from National Research Council Canada to Develop Genetic Biomarkers for Cardiovascular Disease
Med BioGene Inc. announced that it has received a $307,000 contribution from the National Research Council Canada Industrial Research Assistance Program (NRC-IRAP) to develop genetic biomarkers for cardiovascular disease (CVD).
"We believe that Med BioGene's expertise in gene expression and the continued development and validation of our genetic signatures for CVD, coupled with access to world-class scientific knowledge and blood samples from patients with confirmed CVD through our collaboration with the University of Ottawa Heart Institute, will create an effective environment for the development of a novel tool for use in screening and in improving diagnosis, prognosis and treatment decisions for patients suffering from CVD" said Erinn Broshko, Chief Executive Officer of MBI.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.